Clinical and pathophysiological aspects of sickle cell anemia

Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, Second Edition

Volumn , Issue , 2009, Pages 437-496

  Steinberg, Martin H ^a   Ohene Frempong, Kwaku ^b   Heeney, Matthew M ^c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84932641769     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511596582.027     Document Type: Chapter

References (398)

1. Ranney HM. Historical Milestones. In: Embury SH, Hebbel RP, MohandasN, SteinbergMH, eds. Sickle CellDisease: Basic Principles and Clinical Practice. 1st ed. New York: Lippincott-Raven; 1994:1-5.
2. Pauling L. Foreword. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. 1st ed. New York: Lippincott-Raven; 1994: xvii-xix.
3. Conley CL. Sickle-cell anemia-the first molecular disease. In: Wintrobe M, ed. Blood, Pure and Eloquent. 1st ed. New York: McGraw-Hill; 1980:319-371.
4. Herrick JB. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch Intern Med. 1910;6:517-521.
5. Savitt TL, Goldberg MF. Herrick's 1910 case report of sickle cell anemia: the rest of the story. JAMA. 1989;261:266-271.
6. Pauling L, Itano H, Singer SJ, Wells IC. Sickle cell anemia: a molecular disease. Science. 1949;110:543-548.
7. Beet EA. The genetics of sickle cell trait in a Bantu tribe. Ann Eugen. 1949;14:279-284.
8. Neel JV. The inheritance of the sickling phenomenon with particular reference to sickle cell disease. Blood. 1951;6:389-412.
9. Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature. 1956;178:792-794.
10. Frempong KO, Steinberg MH. Clinical aspects of sickle cell anemia in adults and children. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management. 1st ed. Cambridge: Cambridge University Press; 2001:611-710.
11. Motulsky AG. Frequency of sickling disorders in US blacks. NEngl J Med. 1973;288:31-33.
12. Ballas SK, Smith ED. Red blood cell changes during the evolution of the sickle cell painful crisis. Blood. 1992;79:2154-2163.
13. West MS, Wethers D, Smith J, Steinberg MH, Coop Study of Sickle Cell Disease. Laboratory profile of sickle cell disease: a cross-sectional analysis. J Clin Epidemiol. 1992;45:893-909.
14. Hayes RJ, Beckford M, Grandison Y, Mason K, Serjeant BE, Serjeant GR. The haematology of steady state homozygous sickle cell disease: frequency distributions variation with age and sex, longitudinal observations. Br J Haematol. 1985;59:369-382.
15. Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. 2006;107(6):2279-2285.
16. De Ceulaer K, Serjeant GR. Acute splenic sequestration in Jamaican adults with homozygous sickle cell disease: a role of alpha thalassaemia. Br J Haematol. 1991;77:563-564.
17. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8(12):1383-1389.
18. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood. Rev 2007;21:37-47.
19. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.NEngl J Med. 2004;350(9):886-895.
20. Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH. Hemolysis-associated priapism in sickle cell disease. Blood. 2005;106(9):3264-3267.
21. Nolan VG, Adewoye A, Baldwin C, et al. Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol. 2006;133(5):570-578.
22. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288-294.
23. Adams RJ, Kutlar A, McKie V, et al. Alpha thalassemia and stroke risk in sickle cell anemia. Am J Hematol. 1994;45(4): 279-282.
24. Hsu LL, Miller ST, Wright E, et al. Alpha Thalassemia is associated with decreased risk of abnormal TCD ultrasonography in children with sickle cell anemia. J Pediatr Hematol Oncol. 2003;25(8):622-628.
25. Lezcano NE, Odo N, Kutlar A, Brambilla D, Adams RJ. Regular transfusion lowers plasma free hemoglobin in children with sickle-cell disease at risk for stroke. Stroke. 2006;37(6):1424-1426.
26. Kato GJ, Hsieh M, Machado R, et al. Cerebrovascular disease associated with sickle cell pulmonary hypertension. Am J Hematol. 2006;81(7):503-510.
27. Taylor JG, Nolan VG, Kato GJ, Gladwin MT, Steinberg MH. The hyperhemolysis phenotype in sickle cell anemia: increased risk of leg ulcers, priapism, pulmonary hypertension and death with decreased risk of vasoocclusive events. Blood. 2006;108:236a.
28. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease-rates and risk factors. NEngl J Med. 1991;325:11-16.
29. Machado RF, Kyle MA, Martyr S, et al. Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. Br J Haematol. 2007;136(2):319-325.
30. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Longterm oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology. 2006;67(5):1043-1048.
31. Morris CR, Morris SM Jr, Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? AmJ Respir Crit CareMed. 2003;168(1):63-69.
32. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia.NEngl J Med. 1995;332:1317-1322.
33. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289(13):1645-1651.
34. Steinberg MH. Clinical trials in sickle cell disease: adopting the combination chemotherapy paradigm. Am J Hematol. 2008;83(1):1-3.
35. Stuart MJ, Setty BN. Hemostatic alterations in sickle cell disease: relationships to disease pathophysiology. Pediatr Pathol Mol Med. 2001;20(1):27-46.
36. Setty BN, Rao AK, Stuart MJ. Thrombophilia in sickle cell disease: the red cell connection. Blood. 2001;98(12):3228-3233.
37. Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood. 2007; 110(6):2166-2172.
38. Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Blood. 1995;86:776-783.
39. Gaston M, Smith J, Gallagher D, et al. Recruitment in the Cooperative Study of Sickle Cell Disease (CSSCD). Control Clin Trials. 1987;8:131S-140S.
40. Gaston M, Rosse WF. The cooperative study of sickle cell disease: review of study design and objectives. Am J Pediatr Hematol Oncol. 1982;4:197-201.
41. Bainbridge R, Higgs DR, Maude GH, Serjeant GR. Clinical presentation of homozygous sickle cell disease. J Pediatr. 1985;106:881-885.
42. Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;342(2):83-89.
43. Quinn CT, Lee NJ, Shull EP, Ahmad N, Rogers ZR, Buchanan GR. Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn Cohort. Blood. 2008;111(2):544-548.
44. Sebastiani P, Nolan VG, Baldwin CT, et al. Predicting severity of sickle cell disease. Blood. 2007;110:2727-2735.
45. Brown AK, Sleeper LA, Pegelow CH, et al. The influence of infant and maternal sickle cell disease on birth outcome and neonatal course. AmJ Dis Child. 1994;148:1156-1162.
46. Brown AK, Sleeper LA, Miller ST, Pegelow CH, Gill FM, Waclawiw MA. Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease. Am J Dis Child. 1994;148:796-804.
47. Hankins JS, Helton KJ, McCarville MB, Li CS, Wang WC, Ware RE. Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr Blood Cancer. 2007;50:293-297.
48. Platt OS, Rosenstock W, Espeland M. Influence of S hemoglobinopathies on growth and development. N Engl J Med. 1984;311:7-12.
49. Singhal A, Thomas P, Cook R, Wierenga K, Serjeant G. Delayed adolescent growth in homozygous sickle cell disease. Arch Dis Child. 1994;71:404-408.
50. Caruso-Nicoletti M, Mancuso M, Spadaro G, Samperi P, Consalvo C, Schiliro G. Growth and development in white patients with sickle cell diseases. AmJ PediatrHematolOncol. 1992;14(4):285-288.
51. Modebe O, Ifenu SA. Growth retardation in homozygous sickle cell disease: role of calorie intake and possible genderrelated differences. Am J Hematol. 1993;44(3):149-154.
52. Zemel BS, Kawchak DA, Ohene-Frempong K, Schall JI, Stallings VA. Effects of delayed pubertal development, nutritional status, and disease severity on longitudinal patterns of growth failure in children with sickle cell disease. Pediatr Res. 2007;61(5 Pt 1):607-613.
53. Soliman AT, El Banna N, AlSalmi I, De Silva V, Craig A, Asfour M. Growth hormone secretion and circulating insulinlike growth factor-I (IGF-I) and IGF binding protein-3 concentrations in children with sickle cell disease. Metabolism. 1997;46(11):1241-1245.
54. Nunlee-Bland G, Rana SR, Houston-Yu PE, Odonkor W. Growth hormone deficiency in patients with sickle cell disease and growth failure. J Pediatr Endocrinol Metab. 2004;17(4):601-606.
55. Badaloo A, Jackson AA, Jahoor F. Whole body protein turnover and resting metabolic rate in homozygous sickle cell disease. Clin Sci (Lond). 1989;77(1):93-97.
56. Singhal A, Davies P, Sahota A, Thomas PW, Serjeant GR. Resting metabolic rate in homozygous sickle cell disease. Am J Clin Nutr. 1993;57:32-34.
57. Singhal A, Davies P, Wierenga KJ, Thomas P, Serjeant G. Is there an energy deficiency in homozygous sickle cell disease? Am J Clin Nutr. 1997;66(2):386-390.
58. Kopp-Hoolihan LE, van L, Mentzer WC, Heyman MB. Elevated resting energy expenditure in adolescents with sickle cell anemia. J AmDiet Assoc. 1999;99(2):195-199.
59. Borel MJ, Buchowski MS, Turner EA, Peeler BB, Goldstein RE, Flakoll PJ. Alterations in basal nutrient metabolism increase resting energy expenditure in sickle cell disease. AmJ Physiol EndocrinolMetab. 1998;274(2):E357-E364.
60. Salman EK, Haymond MW, Bayne E, et al. Protein and energy metabolism in prepubertal children with sickle cell anemia. Pediatr Res. 1996;40:34-40.
61. Williams R, Olivi S, Li CS, et al. Oral glutamine supplementation decreases resting energy expenditure in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol. 2004;26(10):619-625.
62. Kawchak DA, Schall JI, Zemel BS, Ohene-Frempong K, Stallings VA. Adequacy of dietary intake declines with age in children with sickle cell disease. J AmDiet Assoc. 2007;107(5): 843-848.
63. Jacob E, Miaskowski C, Savedra M, Beyer JE, Treadwell M, Styles L. Changes in sleep, food intake, and activity levels during acute painful episodes in children with sickle cell disease. J Pediatr Nurs. 2006;21(1):23-34.
64. Leonard MB, Zemel BS, Kawchak DA, Ohene-Frempong K, Stallings VA. Plasma zinc status, growth, and maturation in children with sickle cell disease. J Pediatr. 1998;132(3 Pt 1): 467-471.
65. Gupta VL, Chaubey BS. Efficacy of zinc therapy in prevention of crisis in sickle cell anemia: a double blind randomized controlled clinical trial. J Assoc Physicians India. 1995;43:467-469.
66. Prasad AS, Beck FWJ, Kaplan J, et al. Effect of zinc supplementation on incidence of infections and hospital admissions in sickle cell disease (SCD). Am J Hematol. 1999;61(3):194-202.
67. Schall JI, Zemel BS, Kawchak DA, Ohene-Frempong K, Stallings VA. Vitamin A status, hospitalizations, and other outcomes in young children with sickle cell disease. J Pediatr. 2004;145(1):99-106.
68. Buison AM, Kawchak DA, Schall J, Ohene-Frempong K, Stallings VA, Zemel BS. Low vitamin D status in children with sickle cell disease. J Pediatr. 2004;145(5):622-627.
69. Rodriguez-Cortes HM, Griener JC, Hyland K, et al. Plasma homocysteine levels and folate status in children with sickle cell anemia. J Pediatr Hematol Oncol. 1999;21(3):219-223.
70. Wang WC. The pathophysiology, prevention, and treatment of stroke in sickle cell disease. Curr Opin Hematol. 2007;14(3):191-197.
71. Wang WC. Central nervous system complications of sickle cell disease in children: an overview. Child Neuropsychol. 2007;13(2):103-119.
72. Platt OS. Prevention and management of stroke in sickle cell anemia. Hematology Am Soc Hematol Educ Program. 2006;54-57.
73. DeBaun MR, Derdeyn CP, McKinstry RC, III. Etiology of strokes in children with sickle cell anemia. Ment Retard Dev Disabil Res Rev. 2006;12(3):192-199.
74. Adams R, McKie V, Nichols F, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease.NEngl J Med. 1992;326:605-610.
75. Adams RJ. Neurologic complications. In: Embury SH, Hebbel RP, MohandasN, SteinbergMH, eds. Sickle CellDisease: Basic Principles and Clinical Practice. 1 ed. New York: Raven Press; 1994:599-621.
76. Milbauer LC, Wei P, Enenstein J, et al. Genetic endothelial systems biology of sickle stroke risk. Blood. 2008:111:3872-3879.
77. WangWC, Langston JW, Steen RG, et al. Abnormalities of the central nervous system in very young children with sickle cell anemia. J Pediatr. 1998;132(6):994-998.
78. Scothorn DJ, Price C, Schwartz D, et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr. 2002;140(3):348-354.
79. Dobson SR, Holden KR, Nietert PJ, et al. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood. 2002;99(9):3144-3150.
80. Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr. 1992;120:360-366.
81. Strouse JJ, Hulbert ML, DeBaun MR, Jordan LC, Casella JF. Primary hemorrhagic stroke in children with sickle cell disease is associated with recent transfusion and use of corticosteroids. Pediatrics. 2006;118(5):1916-1924.
82. Kirkham FJ, Hewes DKM, Prengler M, Wade A, Lane R, Evans JPM. Nocturnal hypoxaemia and central-nervous-system events in sickle-cell disease. Lancet. 2001;357(9269):1656-1659.
83. Powars D, Wilson B, Imbus C, et al. The natural history of stroke in sickle cell disease. Am JMed. 1978;65:461-470.
84. Francis RB, Jr., Hebbel RP. Hemostasis. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. 1st ed. New York: Lippincott-Raven; 1994:299-310.
85. Houston PE, Rana S, Sekhsaria S, Perlin E, Kim KS, Castro OL. Homocysteine in sickle cell disease: relationship to stroke. Am J Med. 1997;103(3):192-196.
86. Van Der Dijs FPL, Schnog JJB, Brouwer DAJ, et al. Elevated homocysteine levels indicate suboptimal folate status in pediatric sickle cell patients. Am J Hematol. 1998;59(3):192-198.
87. Pegelow CH, Colangelo L, Steinberg M, et al. Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. Am JMed. 1997;102:171-177.
88. Bernaudin F, Verlhac S, Coic L, et al. High LDH level, G6PD deficiency and absence of alpha-thalassemia are significant independent risk factors of abnormally high cerebral velocities in patients with sickle cell anemia. Blood. 2008;112: 4314-4317.
89. O'Driscoll S, Height SE, Dick MC, Rees DC. Serum lactate dehydrogenase activity as a biomarker in children with sickle cell disease. Br J Haematol. 2008:140(2):206-209.
90. Powars DR, Conti PS, Wong WY, et al. Cerebral vasculopathy in sickle cell anemia: diagnostic contribution of positron emission tomography. Blood. 1999;93(1):71-79.
91. Reed W, Jagust W, AlMateen M, Vichinsky E. Role of positron emission tomography in determining the extent of CNS ischemia in patients with sickle cell disease. Am J Hematol. 1999;60(4):268-272.
92. Ohene-Frempong K. Stroke in sickle cell disease: demographic, clinical, and therapeutic considerations. Semin Hematol. 1991;28(3):213-219.
93. Berkelhammer LD, Williamson AL, Sanford SD, et al. Neurocognitive sequelae of pediatric sickle cell disease: a review of the literature. Child Neuropsychol. 2007;13(2):120-131.
94. Tarazi RA, Grant ML, Ely E, Barakat LP. Neuropsychological functioning in preschool-age children with sickle cell disease: the role of illness-related and psychosocial factors. Child Neuropsychol. 2007;13(2):155-172.
95. Switzer JA, Hess DC, Nichols FT, Adams RJ. Pathophysiology and treatment of stroke in sickle-cell disease: present and future. Lancet Neurol. 2006;5(6):501-512.
96. Hulbert ML, Scothorn DJ, Panepinto JA, et al. Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia. J Pediatr. 2006;149(5):710-712.
97. PegelowCH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 1995;126:896-899.
98. Cohen AR, Martin MB, Silber JH, Kim HC, Ohene-Frempong K, Schwartz E. A modified transfusion program for prevention of stroke in sickle cell disease. Blood. 1992;79:1657-1661.
99. Singer ST, Quirolo K, Nishi K, Hackney-Stephens E, Evans C, Vichinsky EP. Erythrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload. J Clin Apher. 1999;14(3):122-125.
100. Fryer RH, Anderson RC, Chiriboga CA, Feldstein NA. Sickle cell anemia with moyamoya disease: outcomes after EDAS procedure. Pediatr Neurol. 2003;29(2):124-130.
101. Ware RE, Zimmerman SA, Sylvestre PB, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr. 2004;145(3):346-352.
102. Adams RJ. Stroke prevention and treatment in sickle cell disease. Arch Neurol. 2001;58(4):565-568.
103. Adams RJ, McKie VC, Brambilla D, et al. Stroke prevention trial in sickle cell anemia. Control Clin Trials. 1998;19(1):110-129.
104. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography [see comments].NEngl J Med. 1998;339(1):5-11.
105. Sebastiani P, Ramoni MF, Nolan V, Baldwin CT, Steinberg MH. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet. 2005;37(4):435-440.
106. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353(26):2769-2778.
107. Zimmerman SA, Schultz WH, Burgett S, Mortier NA, Ware RE. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood. 2007;110:1043-1047.
108. Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood. 2005;105(7): 2685-2690.
109. Kratovil T, Bulas D, Driscoll MC, Speller-Brown B, McCarter R, Minniti CP. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease. Pediatr Blood Cancer. 2006;47(7):894-900.
110. Kinney TR, Sleeper LA, Wang WC, et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. Pediatrics. 1999;103(3):640-645.
111. Armstrong FD, Thompson RJ Jr, Wang W, et al. Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease. Pediatrics. 1996;97:864-870.
112. Shields RWJr, Harris JW, Clark M.Mononeuropathy in sickle cell anemia: anatomical and pathophysiological basis for its rarity. Muscle Nerve. 1991;14:370-374.
113. Imbus CE, Warner J, Smith E, Pegelow CH, Allen JP, Powars DR. Peripheral neuropathy in lead-intoxicated sickle cell patients. Muscle Nerve. 1978;1:168-171.
114. Donegan JO, Lobel JS, Gluckman JL. Otolaryngologic manifestations of sickle cell disease. J Otolaryngol. 1982;3:141-144.
115. Curran EL, Fleming JC, Rice K, Wang WC. Orbital compression syndrome in sickle cell disease. Ophthalmology. 1997;104(10):1610-1615.
116. Koduri PR. Acute splenic sequestration crisis in adults with sickle cell anemia. Am J Hematol. 2007;82(2):174-175.
117. Neonato MG, Guilloud-Bataille M, Beauvais P, et al. Acute clinical events in 299 homozygous sickle cell patients living in France. French Study Group on Sickle Cell Disease. Eur J Haematol. 2000;65(3):155-164.
118. Tarer V, Etienne-Julan M, Diara JP, et al. Sickle cell anemia in Guadeloupean children: pattern and prevalence of acute clinical events. Eur J Haematol. 2006;76(3):193-199.
119. Wright JG, Hambleton IR, Thomas PW, Duncan ND, Venugopal S, Serjeant GR. Postsplenectomy course in homozygous sickle cell disease. J Pediatr. 1999;134(3):304-309.
120. Manci EA, Culberson DE, Yang YM, et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol. 2003;123(2):359-365.
121. Chopra R, Al-Mulhim AR, Al-Baharani AT. Fibrocongestive splenomegaly in sickle cell disease: a distinct clinicopathological entity in the Eastern province of Saudi Arabia. Am J Hematol. 2005;79(3):180-186.
122. Al-Salem AH. Indications and complications of splenectomy for children with sickle cell disease. J Pediatr Surg. 2006;41(11):1909-1915.
123. Zimmerman SA, Davis JS, Schultz WH, Ware RE. Subclinical parvovirus B19 infection in children with sickle cell anemia. J Pediatr Hematol Oncol. 2003;25(5):387-389.
124. Krishnamurti L, Lanford L, Munoz R. Life threatening parvovirus B19 and herpes simplex virus associated acute myocardial dysfunction in a child with homozygous sickle cell disease. Pediatr Blood Cancer. 2007;49:1019-1021.
125. Bakhshi S, Sarnaik SA, Becker C, Shurney WW, Nigro M, Savasan S. Acute encephalopathy with parvovirus B19 infection in sickle cell disease. Arch Dis Child. 2002;87(6):541-542.
126. Wierenga KJ, Serjeant BE, Serjeant GR. Cerebrovascular complications and parvovirus infection in homozygous sickle cell disease. J Pediatr. 2001;139(3):438-442.
127. Smith-Whitley K, Zhao H, Hodinka RL, et al. Epidemiology of human parvovirus B19 in children with sickle cell disease. Blood. 2004;103(2):422-427.
128. Serjeant BE, Hambleton IR, Kerr S, Kilty CG, Serjeant GR. Haematological response to parvovirus B19 infection in homozygous sickle-cell disease. Lancet. 2001;358(9295): 1779-1780.
129. Lane PK, Embury SH, Toy PT. Oxygen-induced marrow red cell hypoplasia leading to transfusion in sickle painful crisis. Am J Hematol. 1988;27:67-68.
130. Embury SH, Garcia JF, Mohandas N, Pennathur-Das R, Clark MR. Effects of oxygen inhalation on endogenous erythropoietin kinetics erythropoiesis and properties of blood cells in sickle cell anemia.NEngl J Med. 1984;311:291-295.
131. Sherwood JB, Goldwasser E, Chilcote R, Carmichael LD, Nagel RL. Sickle cell anemia patients have low erythropoietin levels for their degree of anemia. Blood. 1986;67:46-49.
132. Cazzola M, Guarnone R, Cerani P, Centenara E, Rovati A, Beguin Y. Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood. 1998;91:2139-2145.
133. Little JA, McGowan VR, Kato GJ, et al. Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica. 2006;91(8):1076-1083.
134. Mollapour E, Porter JB, Kaczmarski R, Linch DC, Roberts PJ. Raised neutrophil phospholipase A2 activity and defective priming of NADPH oxidase and phospholipase A2 in sickle cell disease. Blood. 1998;91(9):3423-3429.
135. Wright J, Thomas P, Serjeant GR. Septicemia caused by Salmonella infection: An overlooked complication of sickle cell disease. J Pediatr. 1997;130:394-399.
136. Magnus SA, Hambleton IR, Moosdeen F, Serjeant GR. Recurrent infections in homozygous sickle cell disease. Arch Dis Child. 1999;80(6):537-541.
137. Overturf GD. Infections and immunizations of children with sickle cell disease. Adv Pediatr Infect Dis. 1999;14:191-218.
138. Bagasra O, Steiner RM, Ballas SK, et al. Viral burden and disease progression in HIV-1-infected patients with sickle cell anemia. Am J Hematol. 1998;59(3):199-207.
139. Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. Pediatrics. 1989;84:500-508.
140. Gaston MH, Verter J, Woods G, et al. Prophylaxsis with oral penicillin in children with sickle cell anemia. N Engl J Med. 1986;314:1593-1599.
141. Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44(11):1428-1433.
142. Davies EG, Riddington C, Lottenberg R, Dower N. Pneumococcal vaccines for sickle cell disease. CochraneDatabase Syst Rev. 2004;(1):CD003885.
143. Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. J Pediatr. 1995;127:685-690.
144. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drugresistant Streptococcus pneumoniae. N Engl J Med. 2006; 354(14):1455-1463.
145. Adamkiewicz TV, Sarnaik S, Buchanan GR, et al. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr. 2003;143(4):438-444.
146. Hill PC, Onyeama CO, Ikumapayi UN, et al. Bacteraemia in patients admitted to an urban hospital in West Africa. BMC Infect Dis. 2007;7:2.
147. Hill PC, Akisanya A, Sankareh K, et al. Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian villagers. Clin Infect Dis. 2006;43(6):673-679.
148. Levine OS, O'Brien KL, Knoll M, et al. Pneumococcal vaccination in developing countries. Lancet. 2006;367(9526):1880-1882.
149. Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: Incidence and risk factors. Blood. 1994;84:643-649.
150. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl JMed. 2000;342(25):1855-1865.
151. Vichinsky E, Williams R, Das M, et al. Pulmonary fat embolism: a distinct cause of severe acute chest syndrome in sickle cell anemia. Blood. 1994;83:3107-3112.
152. Bellet PS, Kalinyak KA, Shukla R, Gelfand MJ, Rucknagel DL. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases.NEngl J Med. 1995;333:699-703.
153. Rackoff WR, Kunkel N, Silber JH, Asakura T, Ohene-Frempong K. Pulse oximetry and factors associated with hemoglobin oxygen desaturation in children with sickle cell disease. Blood. 1993;81:3422-3427.
154. Styles LA, Schalkwijk CG, Aarsman AJ, Vichinsky EP, Lubin BH, Kuypers FA. Phospholipase A2 levels in acute chest syndrome of sickle cell disease. Blood. 1996;87:2573-2578.
155. Styles LA, Aarsman AJ, Vichinsky EP, Kuypers FA. Secretory phospholipase A2 predicts impending acute chest syndrome in sickle cell disease. Blood. 2000;96(9):3276-3278.
156. Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr. 2001;139(6):785-789.
157. Styles LA, Abboud M, Larkin S, Lo M, Kuypers FA. Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2. Br J Haematol. 2007;136(2):343-344.
158. Kuypers FA, Styles LA. The role of secretory phospholipase A2 in acute chest syndrome. CellMol Biol. 2004;50(1):87-94.
159. Naprawa JT, Bonsu BK, Goodman DG, Ranalli MA. Serum biomarkers for identifying acute chest syndrome among patients who have sickle cell disease and present to the emergency department. Pediatrics. 2005;116(3):e420-e425.
160. Dworkis DA, Nolan VG, McMahon L, Klings ES, Steinberg MH. Predicting acute chest syndrome in sickle cell disease patients hospitalized for acute vasoocclusive events. Blood. 2007.
161. Gladwin MT, Schechter AN, Shelhamer JH, Ognibene FP. The acute chest syndrome in sickle cell disease-Possible role of nitric oxide in its pathophysiology and treatment. Am J Respir Crit CareMed. 1999;159(5):1368-1376.
162. Kinney TR, Ware RE. The adolescent with sickle cell anemia. Hematol Oncol Clin North Am. 1996;10:1255-1264.
163. Kell RS, Kliewer W, Erickson MT, Ohene-Frempong K. Psychological adjustment of adolescents with sickle cell disease: relations with demographic, medical, and family competence variables. J Pediatr Psychol. 1998;23(5):301-312.
164. Treadwell MJ, Gil KM. Psychosocial Aspects. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. New York: Lippincott-Raven; 1994:517-530.
165. Adewoye AH, Steinberg MH. Hemoglobinopathies in pregnancy. In: Bick RL, Frenkel EP, Baker WF, Sarode R, eds. Hematological Complications in Obstetrics, Pregnancy and Gynecology. Cambridge: Cambridge University Press; 2006: 442-468.
166. Serjeant GR, Hambleton I, Thame M. Fecundity and pregnancy outcome in a cohort with sickle cell-haemoglobin C disease followed from birth. Br J Obstet Gynaecol. 2005;112(9):1308-1314.
167. Anyaegbunam A, Mikhail M, Axioitis C, Morel MI, Merkatz IR. Placental histology and placental/fetal weight ratios in pregnant women with sickle cell disease: relationship to pregnancy outcome. J Assoc AcadMinor Phys. 1994;5(3):123-125.
168. Decastel M, Leborgne-Samuel Y, Alexandre L, Merault G, Berchel C. Morphological features of the human umbilical vein in normal, sickle cell trait, and sickle cell disease pregnancies. Hum Pathol. 1999;30(1):13-20.
169. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation. 2002;9(3):147-160.
170. Sun PM, Wilburn W, Raynor BD, Jamieson D. Sickle cell disease in pregnancy: twenty years of experience at Grady Memorial Hospital, Atlanta, Georgia. Am J Obstet Gynecol. 2001;184(6):1127-1130.
171. Williams-Murphy M, Thorneycroft I, Little F, Hoff C. Pregnancy outcome in women with sickle-cell disease in Mobile Alabama. J InvestMed. 1999;47:123A.
172. Koshy M, Burd L. Obstetric and Gynecologic Issues. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. 1st ed. New York: Lippincott-Raven; 1994:689-702.
173. Smith JA, Espeland M, Bellevue R, Bonds D, Brown AK, Koshy M. Pregnancy in sickle cell disease: Experience of the cooperative study of sickle cell disease. Obstet Gynecol. 1996;87:199-204.
174. Serjeant GR, Loy LL, Crowther M, Hambleton IR, Thame M. Outcome of pregnancy in homozygous sickle cell disease. Obstet Gynecol. 2004;103(6):1278-1285.
175. Howard RJ, Tuck SM, Pearson TC. Pregnancy in sickle cell disease in the UK: results of a multicentre survey of the effect of prophylactic blood transfusion on maternal and fetal outcome. Br J Obstet Gynaecol. 1995;102:947-951.
176. Powars DR, Sandhu M, Nilland-Weiss J, Johnson C, Bruce S, Manning PR. Pregnancy in sickle cell disease. Obstet Gynecol. 1986;67:217-228.
177. Fairley CK, Smoleniec JS, Caul OE, Miller E. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19 infection. Lancet. 1995;346(8986):1335-1337.
178. Selbing A, Josefsson A, Dahle LO, Lindgren R. Parvovirus B19 infection during pregnancy treated with high-dose intravenous gammaglobulin. Lancet. 1995;345(8950):660-661.
179. Morris JS, Dunn DT, Poddar D, Serjeant GR. Haematological risk factors for pregnancy outcome in Jamaican women with homozygous sickle cell disease. Br J Obstet Gynaecol. 1994;101(9):770-773.
180. Koshy M, Burd L, Wallace D, Moawad A, Baron J. Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study. N Engl J Med. 1988;319:1447-1452.
181. El-Shafei AM, Kaur Dhaliwal J, Kaur Sandhu A, Rashid Al-Sharqi M. Indications for blood transfusion in pregnancy in sickle cell disease. Aust NZ J Obstet Gynaecol. 1995;35:405-408.
182. Mahomed K. Prophylactic versus selective blood transfusion for sickle cell anaemia during pregnancy. Cochrane Database Syst Rev. 2000;CD000040.
183. Koshy M, Burd L.Mangement of pregnancy in sickle cell syndromes. Hematol Oncol Clin North Am. 1991;5:585-596.
184. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107(6):1453-1472.
185. Halvorson DJ, McKie V, McKie K, Ashmore PE, Porubsky ES. Sickle cell disease and tonsillectomy-Preoperative management and postoperative complications. Arch Otolaryngol Head Neck Surg. 1997;123(7):689-692.
186. Scott-Conner CEH, Brunson CD. The pathophysiology of the sickle hemoglobinopathies and implications for perioperative management. Am J Surg. 1994;168:268-274.
187. Scott-Conner CEH, Brunson CD. Surgery and Anesthesia. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. 1st ed. New York: Lippincott-Raven; 1994:809-827.
188. Firth PG. Anaesthesia for peculiar cellsa century of sickle cell disease. Br J Anaesth. 2005;95(3):287-299.
189. Firth PG, Head CA. Sickle cell disease and anesthesia. Anesthesiology. 2004;101(3):766-785.
190. Koshy M, Weiner SJ, Miller ST, et al. Surgery and anesthesia in sickle cell disease. Blood. 1995;86:3676-3684.
191. Stein RE, Urbaniak J. Use of the tourniquet during surgery in patients with sickle cell hemoglobinpathies. Clin Orthop. 1980;151:231-233.
192. Vipond AJ, Caldicott LD. Major vascular surgery in a patient with sickle cell disease. Anaesthesia. 1998;53(12):1204-1206.
193. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. N Engl J Med. 1995;333:206-213.
194. Crawford MW, Speakman M, Carver ED, Kim PC. Acute chest syndrome shows a predilection for basal lung regions on the side of upper abdominal surgery. Can J Anaesth. 2004;51(7):707-711.
195. Wales PW, Carver E, Crawford MW, Kim PCW. Acute chest syndrome after abdominal surgery in children with sickle cell disease: is a laparoscopic approach better? J Pediatr Surg. 2001;36(5):718-721.
196. Buck J, Casbard A, Llewelyn C, Johnson T, Davies S, Williamson L. Preoperative transfusion in sickle cell disease: a survey of practice in England. Eur J Haematol. 2005; 75(1):14-21.
197. Fu T, Corrigan NJ, Quinn CT, Rogers ZR, Buchanan GR.Minor elective surgical procedures using general anesthesia in children with sickle cell anemia without pre-operative blood transfusion. Pediatr Blood Cancer. 2005;45(1):43-47.
198. Waldron P, Pegelow C, Neumayr L, et al. Tonsillectomy, adenoidectomy, and myringotomy in sickle cell disease: perioperative morbidity. Preoperative Transfusion in Sickle Cell Disease Study Group. J Pediatr Hematol Oncol. 1999;21(2): 129-135.
199. Duke RL, Scott JP, Panepinto JA, Flanary VA. Perioperative management of sickle cell disease children undergoing adenotonsillectomy. Otolaryngol Head Neck Surg. 2006;134(3):370-373.
200. Griffin TC, Buchanan GR. Elective surgery in children with sickle cell disease without preoperative blood transfusion. J Pediatr Surg. 1993;28:681-685.
201. Jeng M, Feusner J, Vichinksy EP. Risk factors for central venous catheter infections in sickle cell disease. 23rd Annual Meeting of the National Sickle Cell Disease Program. 1999;106.
202. Wagner SC, Eschelman DJ, Gonsalves CF, Bonn J, Sullivan KL. Infectious complications of implantable venous access devices in patients with sickle cell disease. J Vasc Interv Radiol. 2004;15(4):375-378.
203. Zarrouk V, Habib A, Zahar JR, et al. Blood. stream infection in adults with sickle cell disease: association with venous catheters, Staphylococcus aureus, and bone-joint infections. Medicine (Baltimore). 2006;85(1):43-48.
204. Chulamokha L, Scholand SJ, Riggio JM, Ballas SK, Horn D, DeSimone JA. Bloodstream infections in hospitalized adults with sickle cell disease: a retrospective analysis. Am J Hematol. 2006;81(10):723-728.
205. Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med. 1991;325:1476-1481.
206. Milner PF, Kraus AP, Sebes JI, et al. Osteonecrosis of the humeral head in sickle cell disease. Clin Orthop. 1993;289: 136-143.
207. Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients.Medicine (Baltimore). 2005;84(6):363-376.
208. Hernigou P, Bachir D, Galacteros F. The natural history of symptomatic osteonecrosis in adults with sickle-cell disease. J Bone Joint Surg Am. 2003;85(3):500-504.
209. Hernigou P, Habib A, Bachir D, Galacteros F. The natural history of asymptomatic osteonecrosis of the femoral head in adults with sickle cell disease. J Bone Joint Surg Am. 2006;88(12):2565-2572.
210. Osteonecrosis-etiology, diagnosis, and treatment. American Orthopaedic Association;1997.
211. Ficat R. Idiopathic bone necrosis of the femoral head. Soc Bone Joint Surg. 1985;67:3-9.
212. Aguilar CM, Neumayr LD, Eggleston BE, et al. Clinical evaluation of avascular necrosis in patients with sickle cell disease: Children's Hospital Oakland Hip Evaluation Scale-a modification of the Harris Hip Score. Arch Phys Med Rehabil. 2005;86(7):1369-1375.
213. Mankin H. Nontraumatic necrosis of bone (osteonecrosis). NEngl J Med. 1992;326:1473-1479.
214. Washington E, Root L. Conservative treatment of sickle cell avascular necrosis of the femoral head. J Pediatr Orthop. 1985; 5:192-194.
215. Dunsmore K, Ware R, Frush D, Kinney T. Short-term transfusion therapy for avascular necrosis of the hips in children with sickle cell disease. Int J Pediatr Hematol Oncol. 1995;2:79-83.
216. Hickman JM, Lachiewicz PF. Results and complications of total hip arthroplasties in patients with sickle-cell hemoglobinopathies-Role of cementless components. J Arthroplasty. 1997;12:420-425.
217. Jeong GK, Ruchelsman DE, Jazrawi LM, Jaffe WL. Total hip arthroplasty in sickle cell hemoglobinopathies. J Am Acad Orthop Surg. 2005;13(3):208-217.
218. Mont MA, Carbone JJ, Fairbank AC. Core decompression versus non-operative management for osteonecrosis of the hip. Clin Orthop Rel Res. 1996;324:169-178.
219. Neumayr LD, Aguilar C, Earles AN, et al. Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. J Bone Joint Surg Am. 2006;88(12):2573-2582.
220. Hernigou P, Zilber S, Filippini P, Mathieu G, Poignard A, Galacteros F. Total THA in adult osteonecrosis related to sickle cell disease. Clin Orthop Rel Res. 2008;466(2):300-308.
221. Dorwart BB, Gabuzda T. Symmetric myositis and faciitis: a complication of sickle cell anemia during vasoocclusion. J Rheumatol. 1985;12:590-595.
222. Malekgoudarzi B, Feffer S.Myonecrosis in sickle cell anemia. NEngl J Med. 1999;340(6):483.
223. Kim SK, Miller JH. Natural history and distribution of bone and bone marrow infarction in sickle hemoglobinopathies. J Nucl Med. 2002;43(7):896-900.
224. Ataga KI, Orringer EP. Bone marrownecrosis in sickle cell disease: A description of three cases and a review of the literature. Am JMed Sci. 2000;320(5):342-347.
225. Mankad VN, Williams JP, Harpen MD, et al. Magnetic resonance imaging of bone marrow in sickle cell disease: clinical, hematologic, and pathologic correlations. Blood. 1990;75(1):274-283.
226. Abbiyesuku FM, Osotimehin BO. Anterior pituitary gland assessment in sickle cell anaemia patients with delayed menarche. Afr JMedMed Sci. 1999;28(1-2):65-69.
227. Abbasi AA, Prasad AS, Ortega J, Congco E, Oberleas D. Gonadal function abnormalities in sickle cell anemia: studies inmale patients. Ann InternMed. 1976;85:601-605.
228. Osegbe DN, Akinyanju OO. Testicular dysfunction in men with sickle cell disease. Postgrad Med J. 1987;63(736):95-98.
229. Li M, Fogarty J, Whitney KD, Stone P. Repeated testicular infarction in a patient with sickle cell disease: a possible mechanism for testicular failure. Urology. 2003;62(3):551.
230. Landefeld CS, Schambelan M, Kaplan SL, Embury SH. Clomiphene-responsive hypogonadism in sickle cell anemia. Ann InternMed. 1983;99(4):480-483.
231. Miller RG, Segal JB, Ashar BH, et al. High prevalence and correlates of low bone mineral density in young adults with sickle cell disease. Am J Hematol. 2006;81(4):236-241.
232. Voskaridou E, Stoupa E, Antoniadou L, et al. Osteoporosis and osteosclerosis in sickle cell/beta-thalassemia: the role of the RANKL/osteoprotegerin axis. Haematologica. 2006;91(6):813-816.
233. Lal A, Fung EB, Pakbaz Z, Hackney-Stephens E, Vichinsky EP. Bone mineral density in children with sickle cell anemia. Pediatr Blood Cancer. 2006;47(7):901-906.
234. Van Der Dijs FP, Van Der Klis FR, Muskiet FD, Muskiet FA. Serum calcium and vitamin D status of patients with sickle cell disease in Curacao.AnnClinBiochem. 1997;34(Pt 2):170-172.
235. Almeida A, Roberts I. Bone involvement in sickle cell disease. Br J Haematol. 2005;129(4):482-490.
236. Mohammed S, Addae S, Suleiman S, et al. Serum calcium, parathyroid hormone, and vitamin D status in children and young adults with sickle cell disease. Ann Clin Biochem 1993;30(Pt 1):45-51.
237. Adewoye AH, Chen TC, Ma Q, et al. Sickle cell bone disease: Response to vitamin D and calcium. Am J Hematol. 2008;83(4):271-274.
238. Saad STO, Costa FF. Glucose-6-phosphate dehydrogenase deficiency and sickle cell disease in Brazil. Hum Hered. 1992;42:125-128.
239. Phillips G Jr, Becker B, Keller VA, Hartman J. Hypothyroidism in adults with sickle cell anemia. Am J Med. 1992; 92:567-570.
240. Parshad O, Stevens MC, Hudson C, et al. Abnormal thyroid hormone and thyrotropin levels in homozygous sickle cell disease. Clin Lab Haematol. 1989;11(4):309-315.
241. el-Hazmi MA, Bahakim HM, Al-Fawaz I. Endocrine functions in sickle cell anaemia patients. J TropPediatr. 1991;38(6):307-313.
242. Somjee SS, Warrier RP, Thomson JL, Ory-Ascani J, Hempe JM. Advanced glycation end-products in sickle cell anaemia. Br J Haematol. 2005;128(1):112-118.
243. Fung EB, Harmatz PR, Lee PD, et al. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol. 2006;135(4):574-582.
244. Collins FS, Orringer EP. Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies. Am J Med. 1982;73(6):814-821.
245. Taylor JG, Ackah D, Cobb C, et al. Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. Am J Hematol. 2008;83:6-14.
246. Kato GJ, Onyekwere OC, Gladwin MT. Pulmonary hypertension in sickle cell disease: relevance to children. Pediatr Hematol Oncol. 2007;24(3):159-170.
247. Castro O, Hoque M, Brown BD. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood. 2003;101(4):1257-1261.
248. Castro O, Gladwin MT. Pulmonary hypertension in sickle cell disease: mechanisms, diagnosis, and management. Hematol Oncol Clin North Am. 2005;19(5):881-896.
249. Ataga KI, Moore CG, Jones S, et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol. 2006;134(1):109-115.
250. Darbari DS, Kple-Faget P, Kwagyan J, Rana S, Gordeuk VR, Castro O. Circumstances of death in adult sickle cell disease patients. Am J Hematol. 2006; 80(11):858-863.
251. Sutton LL, Castro O, Cross DJ, Spencer JE, Lewis JF. Pulmonary hypertension in sickle cell disease. Am J Cardiol. 1994;74:626-628.
252. Ataga KI, Sood N, De GG, et al. Pulmonary hypertension in sickle cell disease. Am J Med. 2004;117(9):665-669.
253. De Castro LM, Jonassaint JC, Graham FL, Ashley-Koch A, Telen MJ. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol. 2008;83(1):19-25.
254. Haque AK, Gokhale S, Rampy BA, Adegboyega P, Duarte A, Saldana MJ. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol. 2002;33(10):1037-1043.
255. van Beers EJ, van Eck-Smit BL, Mac Gillavry MR, et al. Large and medium sized pulmonary artery obstruction does not play a role of primary importance in the, etiology of sickle cell disease associated pulmonary hypertension. Chest. 2008;ePub.
256. Suell MN, Bezold LI, Okcu MF, Mahoney DH, Jr., Shardonofsky F, Mueller BU. Increased pulmonary artery pressures among adolescents with sickle cell disease. J Pediatr Hematol Oncol. 2005;27(12):654-658.
257. Joyce K, Sable C, Martin B, Minniti CP. Pulmonary artery hypertension in children with sickle cell disease: Is chronic transfusion protective? Blood. 2006;108:356a.
258. Qureshi N, Joyce JJ, Qi N, Chang RK. Right ventricular abnormalities in sickle cell anemia: evidence of a progressive increase in pulmonary vascular resistance. J Pediatr. 2006;149(1):23-27.
259. Ambrusko SJ, Gunawardena S, Sakara A, et al. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediatr Blood Cancer. 2006;47(7):907-913.
260. Liem RI, Willingham NM, Young LT, Thompson AA. Tricuspid regurgitant jet velocity is significantly associated with hemolysis in the evaluation of pulmonary hypertension in children and young adults with sickle cell disease. Blood. 2006;108:356a.
261. Liem RI, Young LT, Thompson AA. Tricuspid regurgitant jet velocity is associated with hemolysis in children and young adults with sickle cell disease evaluated for pulmonary hypertension. Haematologica. 2007;92:1549-1552.
262. Campbell AD, Minniti C, Sable C, et al. Prospective evaluation of the prevalence of elevated tricuspid regurgitant jet velocity and associated clinical and echocardiographic factors in children and adolescents with sickle cell disease. Blood. 2007;110:993a.
263. Machado RF, Gladwin MT. Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. Br J Haematol. 2005;129(4):449-464.
264. Mekontso Dessap A, Leon R, Habib A, et al. Pulmonary Hypertension and Cor Pulmonale during Severe Acute Chest Syndrome in Sickle Cell Disease. Am J Respir Crit Care Med. 2008;177(6):646-653.
265. Machado RF, Anthi A, Steinberg MH, et al. N-terminal probrain natriuretic peptide levels and risk of death in sickle cell disease. JAMA. 2006;296(3):310-318.
266. Kato GJ, Martyr S, Blackwelder WC, et al. Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. Br J Haematol. 2005;130(6):943-953.
267. Ataga KI, Moore CG, Hillery CA, et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica. 2008;93(1):20-26.
268. Gordeuk VR, Sachdev V, Taylor JG, Gladwin MT, Kato G, Castro OL. Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency. Am J Hematol. 2008;83(1):15-18.
269. Morris CR, Suh JH, Hagar W, et al. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood. 2008;111(1):402-410.
270. Ameshima S, Golpon H, Cool CD, et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res. 2003;92(10):1162-1169.
271. Nichols WC, Koller DL, Slovis B, et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet. 1997;15(3):277-280.
272. Machado RD, Pauciulo MW, Thomson JR, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet. 2001;68(1):92-102.
273. Santoli F, Zerah F, Vasile N, Bachir D, Galacteros F, Atlan G. Pulmonary function in sickle cell disease with or without acute chest syndrome. Eur Respir J. 1998;12(5):1124-1129.
274. Powars D, Weidman JA, Odom-Maryon T, Niland JC, Johnson C. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine (Baltimore). 1988;67(1):66-76.
275. Akgul F, Yalcin F, Babayigit C, Seyfeli E, Seydaliyeva T, Gali E. Right ventricular and pulmonary function in sickle cell disease patients with pulmonary hypertension. Pediatr Cardiol. 2006;27(4):440-446.
276. Zar HA, Wu WW. The inability to detect expired carbon dioxide after endotracheal intubation as a result of one-way valve obstruction of the endotracheal tube. Anesth Analg. 2001;93(4):971-972, table.
277. Klings ES, Wyszynski DF, Nolan VG, Steinberg MH. Abnormal pulmonary function in adults with sickle cell anemia. Am J Respir Crit CareMed. 2006;173:1264-1269.
278. Arteta M, Campbell AD, Minniti C, et al. Pulmonary function tests and their correlation with tricuspid regurgitant jet velocity in pediatric sickle cell disease patients. Blood. 2007;110:670a.
279. Knight-Madden JM, Forrester TS, Lewis NA, Greenough A. Asthma in children with sickle cell disease and its association with acute chest syndrome. Thorax. 2005;60(3):206-210.
280. Glassberg J, Spivey JF, Strunk R, Boslaugh S, DeBaun MR. Painful episodes in children with sickle cell disease and asthma are temporally associated with respiratory symptoms. J Pediatr Hematol Oncol. 2006;28(8):481-485.
281. Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood. 2006;108:2923-2927.
282. Boyd JH, Moinuddin A, Strunk RC, DeBaun MR. Asthma and acute chest in sickle-cell disease. Pediatr Pulmonol. 2004;38(3):229-232.
283. Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with increased mortality in individuals with sickle cell anemia. Haematologica. 2007;92(8):1115-1118.
284. Nordness ME, Lynn J, Zacharisen MC, Scott PJ, Kelly KJ. Asthma is a risk factor for acute chest syndrome and cerebral vascular accidents in children with sickle cell disease. Clin Mol Allergy. 2005;3(1):2.
285. Phillips KL, An P, Boyd JH, et al. Major gene effect and additive familial pattern of inheritance of asthma exist among families of probands with sickle cell anemia and asthma. Am J HumBiol. 2007;ePub.
286. Machado RF, Martyr S, Kato GJ, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol. 2005;130(3):445-453.
287. Koshy M, Entsuah R, Koranda A, et al. Leg ulcers in patients with sickle cell disease [see comments]. Blood. 1989;74:1403-1408.
288. Clare A, FitzHenley M, Harris J, Hambleton I, Serjeant GR. Chronic leg ulceration in homozygous sickle cell disease: the role of venous incompetence. Br J Haematol. 2002; 119(2):567-571.
289. Best PJ, Daoud MS, Pittelkow MR, Petitt RM. Hydroxyureainduced leg ulceration in 14 patients. Ann Intern Med. 1998;128(1):29-32.
290. Weinlich G, Schuler G, Greil R, Kofler H, Fritsch P. Leg ulcers associated with long-term hydroxyurea therapy. J Am Acad Dermatol. 1998;39(2 Pt 2):372-374.
291. Ravandi-Kashani F, Cortes J, Cohen P, et al. Cutaneous ulcers associated with hydroxyurea (HU) therapy in myeloproliferative disorders. Blood. 1998;92:248b.
292. Chaine B, Neonato MG, Girot R, Aractingi S. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. Arch Dermatol. 2001;137(4):467-470.
293. Giraldi S, Abbage KT, Marinoni LP, et al. Leg ulcer in hereditary spherocytosis. Pediatr Dermatol. 2003;20(5):427-428.
294. Eckman JR. Leg ulcers in sickle cell disease. Hematol Oncol Clin North Am. 1996;10:1333-1344.
295. Mackenzie RK, Ludlam CA, Ruckley CV, Allan PL, Burns P, Bradbury AW. The prevalence of thrombophilia in patients with chronic venous leg ulceration. J Vasc Surg. 2002;35(4):718-722.
296. Billett HH, Patel Y, Rivers SP. Venous insufficiency is not the cause of leg ulcers in sickle cell disease. Am J Hematol. 1991;37:133-134.
297. Chalchal H, Rodino W, Hussain S, et al. Impaired venous hemodynamics in a minority of patients with chronic leg ulcers due to sickle cell anemia. Vasa. 2001;30(4):277-279.
298. Mohan JS, Vigilance JE, Marshall JM, Hambleton IR, Reid HL, Serjeant GR. Abnormal venous function in patients with homozygous sickle cell (SS) disease and chronic leg ulcers. Clin Sci (Lond). 2000;98(6):667-672.
299. Ademiluyi SA, Rotimi VO, Coker AO, Banjo TO, Akinyanju O. The anaerobic and aerobic bacterial flora of leg ulcers in patients with sickle-cell disease. J Infect. 1988;17:115-120.
300. MacFarlane DE, Baum KF, Serjeant GR. Bacteriology of sickle cell leg ulcers. Trans R Soc Trop Med Hyg. 1986;80:553-556.
301. Sawhney H, Weedon J, Gillette P, Solomon W, Braverman A. Predilection of hemolytic anemia-associated leg ulcers for the medial malleolus. Vasa. 2002;31(3):191-193.
302. Baum KF, MacFarlane DE, Maude GH, Serjeant GR. Topical antibiotics in chronic sickle cell leg ulcers. Trans R Soc Trop Med Hyg. 1987;81:847-849.
303. Ramos CE, Park JS, Ritchey ML, Benson GS. High flow priapism associated with sickle cell disease. J Urol. 1995; 153:1619-1621.
304. Sharpsteen JR Jr, Powars D, Johnson C, Rogers ZR, Williams WD, Posch RJ.Multisystem damage associated with tricorporal priapism in sickle cell disease. Am JMed. 1993;94:289-295.
305. Burnett AL. Role of nitric oxide in the physiology of erection. Biol Reprod. 1995;52(3):485-489.
306. Burnett AL.Neurophysiology of erectile function: androgenic effects. J Androl. 2003;24(6 Suppl):S2-S5.
307. Burnett AL. Pathophysiology of priapism: dysregulatory erection physiology thesis. J Urol. 2003;170(1):26-34.
308. Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci USA. 2005;102(5):1661-1666.
309. Brandow AM, Rennie KM, Scott JP, Hillery CA, Panepinto JA. Increased red blood cell adhesion is associated with priapism in sickle cell disease. Blood. 2006;108:363a.
310. Mantadakis E, Cavender JD, Rogers ZR, Ewalt DH, Buchanan GR. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol. 1999;21(6):518-522.
311. Fowler JE, Jr., Koshy M, Strub M, Chinn SK. Priapism associated with the sickle cell hemoglobinopathies: Prevalence, natural history and sequelae. J Urol. 1991;145:65-68.
312. Serjeant GR. Sickle Cell Disease. 2nd ed. Oxford: OxfordMedical Publications; 1992.
313. Serjeant GR, De Ceulaer K, Maude GH. Stilboestrol and stuttering priapism in homozygous sickle cell disease. Lancet. 1985;2:1274-1276.
314. Adeyoju AB, Olujohungbe AB, Morris J, et al. Priapism in sickle-cell disease; incidence, risk factors and complications-an international multicentre study. Br J Urol. Int. 2002;90(9):898-902.
315. Hakim LS, Hashmat AI, Macchia RJ. Priapism. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. 1st ed. New York: Lippincott-Raven; 1994:633-643.
316. Miller ST, Rao SP, Dunn EK, Glassberg KI. Priapism in children with sickle cell disease. J Urol. 1995;154:844-847.
317. Chakrabarty A, Upadhyay J, Dhabuwala CB, Sarnaik S, Perlmutter AD, Connor JP. Priapism associated with sickle cell hemoglobinopathy in children: Long-term effects on potency. J Urol. 1996;155:1419-1423.
318. Tarry WF, Duckett JW Jr, Snyder HMI. Urological complications of sickle cell disease in a pediatric population. J Urol. 1987;138:592-594.
319. Kassim AA, Umans H, Nagel RL, Fabry ME. Megalophallus as a sequela of priapism in sickle cell anemia: use of blood oxygen level-dependent magnetic resonance imaging. Urology. 2000;56(3):509.
320. Burnett AL, Allen RP, Tempany CM, Dover GJ, Brendler CB. Evaluation of erectile function in men with sickle cell disease. Urology. 1995;45:657-663.
321. Chinegwundoh F, Anie KA. Treatments for priapism in boys and men with sickle cell disease. Cochrane Database Syst Rev. 2004;(4):CD004198.
322. McCarthy LJ, Vattuone J, Weidner J, et al. Do automated red cell exchanges relieve priapism in patients with sickle cell anemia? Ther Apher. 2000;4(3):256-258.
323. Merritt AL, Haiman C, Henderson SO. Myth: blood transfusion is effective for sickle cell anemia-associated priapism. CJEM. 2006;8(2):119-122.
324. Mantadakis E, Ewalt DH, Cavender JD, Rogers ZR, Buchanan GR. Outpatient penile aspiration and epinephrine irrigation for young patients with sickle cell anemia and prolonged priapism. Blood. 2000;95(1):78-82.
325. Virag R, Bachir D, Lee K, Galacteros F. Preventive treatment of priapism in sickle cell disease with oral and self-administered intracavernous injection of etilefrine. Urology. 1996;47:777-781.
326. Virag R, Bachir D, Floresco J, Galacteros F, Dufour B. Ambulatory treatment and prevention of priapism using alphaagonists. Apropos of 172 cases. Chirurgie. 1997;121:648-652.
327. Bachir D, Virag R, Lee K, et al. Prevention and treatment of erectile disorders in sickle cell disease [in French]. Rev Med Interne. 1997;18(Supp 1):46S-51S.
328. Okpala I, Westerdale N, Jegede T, Cheung B. Etilefrine for the prevention of priapism in adult sickle cell disease. Br J Haematol. 2002;118(3):918-921.
329. Gbadoe AD, Atakouma Y, Kusiaku K, Assimadi JK. Management of sickle cell priapism with etilefrine. Arch Dis Child. 2001;85(1):52-53.
330. Dahm P, Rao DS, Donatucci CF. Antiandrogens in the treatment of priapism. Urology. 2002;59(1):138.
331. Saad ST, Lajolo C, Gilli S, et al. Follow-up of sickle cell disease patients with priapism treated by hydroxyurea. Am J Hematol. 2004;77(1):45-49.
332. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J SexMed. 2006;3(6):1077-1084.
333. Monga M, Broderick GA, Hellstrom WJG. Priapism in sickle cell disease: the case for early implantation of the penile prosthesis. Eur Urol. 1996;30:54-59.
334. Johnson CS, Omata M, Tong MJ, Simmons JF Jr, Weiner J, Tatter D. Liver involvement in sickle cell disease. Medicine. 1985;69:833-837.
335. Wright JG, Cooper P, Malia RG, et al. Activated protein C resistance in homozygous sickle cell disease. Br J Haematol. 1997;96:854-856.
336. Gremse DA, Fillingim E, Hoff CJ, Wells DJ, Boerth RC. Hepatic function as assessed by lidocaine metabolism in sickle cell disease. J Pediatr. 1998;132(6):989-993.
337. Comer GM, Ozick LA, Sachdev RK, et al. Transfusion-related chronic liver disease in sickle cell anemia. AmJ Gastroenterol. 1991;86:1232-1234.
338. Charlotte F, Bachir D, Nénert M, et al. Vascular lesions of the liver in sickle cell disease: a clinicopathological study in 26 living patients. Arch Pathol LabMed. 1995;119:46-52.
339. Achord JL. Gastroenterologic and hepatobiliary manifestations. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. 1st ed. New York: Lippincott-Raven; 1994:663-672.
340. Richard S, Billett HH. Liver function tests in sickle cell disease. Clin Lab Haematol. 2002;24(1):21-27.
341. Ahn H, Li CS, Wang W. Sickle cell hepatopathy: clinical presentation, treatment, and outcome in pediatric and adult patients. Pediatr Blood Cancer. 2005;45(2):184-190.
342. Walker TM, Hambleton IR, Serjeant GR. Gallstones in sickle cell disease: observations from The Jamaican Cohort study. J Pediatr. 2000;136(1):80-85.
343. Haider MZ, Ashebu S, Aduh P, Adekile AD. Influence of athalassemia on cholelithiasis in SS patients with elevated Hb F. Acta Haematol. 1998;100(3):147-150.
344. Chaar V, Keclard L, Etienne-Julan M, et al. UGT1A1 polymorphism outweighs the modest effect of deletional (-3.7 kb) alpha-thalassemia on cholelithogenesis in sickle cell anemia. Am J Hematol. 2006;81(5):377-379.
345. Passon RG, Howard TA, Zimmerman SA, Schultz WH, Ware RE. Influence of bilirubin uridine diphosphateglucuronosyltransferase 1A promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia. J Pediatr Hematol Oncol. 2001;23(7):448-451.
346. Chaar V, Keclard L, Diara JP, et al. Association of UGT1A1 polymorphism with prevalence and age at onset of cholelithiasis in sickle cell anemia. Haematologica. 2005;90(2):188-199.
347. Heeney MM, Howard TA, Zimmerman SA, Ware RE. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia. J Lab Clin Med. 2003;141(4):279-282.
348. Haberkern CM, Neumayr LD, Orringer EP, et al. Cholecystectomy in sickle cell anemia patients: perioperative outcome of 364 cases from the national preoperative transfusion study. Blood. 1997;89:1533-1542.
349. Al-Salem AH, Nourallah H. Sequential endoscopic/laparoscopic management of cholelithiasis and choledocholithiasis in children who have sickle cell disease. J Pediatr Surg. 1997;32(10):1432-1435.
350. Vichinksy E, Gold J, Rule R, et al. Neuropsychological (NP) dysfunction and neuroimaging abnormalities in neurologically intact adult patients with sickle cell disease (SCD). Blood. 2007;110:132a.
351. Serjeant GR, Higgs DR, Hambleton IR. Elderly survivors with homozygous sickle cell disease. N Engl J Med. 2007; 356(6):642-643.
352. Steinberg MH, Ballas SK, Brunson CY, Bookchin R. Sickle cell anemia in septuagenarians. Blood. 1995;86:3997-3998.
353. Rucknagel DL, Hanash SH, Sing CF, Winter WP, Whitten CF, Prasad AS. Age and sex effects on hemoglobin F in sickle cell anemia. In: Stammatoyannopoulos JA, Nienhius AW, eds. Cellular and Molecular Regulation of Hemoglobin Switching. New York: Grune and Stratton; 1979:107-118.
354. Shurafa MS, Prasad AS, Rucknagel DL, Kan YW. Long survival in sickle cell anemia. Am J Hematol. 1982;12:357-365.
355. Liem RI, Calamaras DM, Chhabra MS, Files B, Minniti CP, Thompson AA. Sudden onset blindness in sickle cell disease due to retinal artery occlusion. Pediatr Blood Cancer. 2007;50(3):624-627.
356. Warth JA, Prasad AS, Zwas F, Franke U. Abnormal dark adaptation in sickle cell anemia. J Lab Clin Med. 1981;98:189-194.
357. Serjeant GR, Serjeant BE, Condon PI. The conjunctival sign in sickle cell anemia. A relationship with irreversibly sickled cells. JAMA. 1972;219:1428-1431.
358. Acar P, Maunoury C, de MM, Dulac Y. Abnormalities of myocardial perfusion in sickle cell disease in childhood: a study of myocardial scintigraphy. Arch Mal Coeur Vaiss. 2003;96(5):507-510.
359. Zilberman MV, Du W, Das S, Sarnaik SA. Evaluation of left ventricular diastolic function in pediatric sickle cell disease patients. Am J Hematol. 2007;82(6):433-438.
360. Leight L, Snider TH, Clifford GO, Hellems HK. Hemodynamic studies in sickle cell anemia. Circulation. 1954;10:653-662.
361. Covitz W, Espeland M, Gallagher D, Hellenbrand W, Leff S, Talner N. The heart in sickle cell anemia-The cooperative study of sickle cell disease (CSSCD). Chest. 1995;108:1214-1219.
362. Braden DS, Covitz W, Milner PF. Cardiovascular function during rest and exercise in patients with sicklecellanemia and coexisting alpha thalassemia-2. Am J Hematol. 1996;52:96-102.
363. Sachdev V, Machado RF, Shizukuda Y, et al. Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J AmColl Cardiol. 2007;49(4):472-479.
364. Covitz W. Cardiac Disease. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. 1st ed. New York: Lippincott-Raven; 1994:725-734.
365. Martin CR, Johnson CS, Cobb C, Tatter D, Haywood LJ. Myocardial infarction in sickle cell disease. J Natl Med Assoc. 1996;88(7):428-432.
366. James TN, Riddick L, Massing GK. Sickle cells and sudden death: morphologic abnormalities of the cardiac conduction system. J Lab ClinMed. 1994;124:507-520.
367. Romero Mestre JC, Hernandez A, Agramonte O, Hernandez P. Cardiovascular autonomic dysfunction in sickle cell anemia: a possible risk factor for sudden death? Clin Auton Res. 1997;7(3):121-125.
368. Ataga KI, Orringer EP. Renal abnormalities in sickle cell disease. Am J Hematol. 2000;63(4):205-211.
369. Guasch A, Cua M, Mitch WE. Early detection and the course of glomerular injury in patients with sickle cell anemia. Kidney Int. 1996;49:786-791.
370. Pham PT, Pham PC, Wilkinson AH, Lew SQ. Renal abnormalities in sickle cell disease. Kidney Int. 2000;57(1):1-8.
371. Platt OS, Brambilla DJ, Rosse WF, et al.Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl JMed. 1994;330(23):1639-1644.
372. Schmitt F, Martinez F, Brillet G, et al. Early glomerular dysfunction in patients with sickle cell anemia. Am J Kidney Dis. 1998;32(2):208-214.
373. Wong WY, Elliott-Mills D, Powars D. Renal failure in sickle cell anemia. Hematol Oncol Clin North Am. 1996;10:1321-1331.
374. Scheinman JI. Sickle cell disease and the kidney. Semin Nephrol. 2003;23(1):66-76.
375. Thompson J, Reid M, Hambleton I, Serjeant GR. Albuminuria and renal function in homozygous sickle cell disease: observations from a cohort study. Arch Intern Med. 2007;167(7):701-708.
376. Powers JS, Krantz SB, Collins JC, et al. Erythropoietin response to anemia as a function of age. J Am Geriatr Soc. 1991;39:30-32.
377. Powars DR, Elliott Mills DD, Chan L. Chronic renal failure in sickle cell disease: Risk factors, clinical course, and mortality. Ann InternMed. 1991;115:614-620.
378. McKie KT, Hanevold CD, Hernandez C, Waller JL, Ortiz L, McKie KM. Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease. J Pediatr Hematol Oncol. 2007;29(3):140-144.
379. Guasch A, Zayas CF, Eckman JR, Muralidharan K, Zhang W, Elsas LJ. Evidence that microdeletions in the a globin gene protect against the development of sickle cell glomerulopathy in humans. J Am Soc Nephrol. 1999;10(5):1014-1019.
380. Falk RJ, Scheinman J, Phillips G, Orringer E, Johnson A, Jennette JC. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensinconverting enzyme.NEngl J Med. 1992;326:910-915.
381. Falk RJ, Jennette JC. Renal disease. In: Embury SH, Hebbel RP, MohandasN, SteinbergMH, eds. Sickle CellDisease: Basic Principles and Clinical Practice. 1st ed. New York: Raven-Lippincott; 1994:673-680.
382. Guasch A, Cua M, You W, Mitch WE. Sickle cell anemia causes a distinct pattern of glomerular dysfunction. Kidney Int. 1997;51:826-833.
383. Guasch A, Navarrete J, Nass K, Zayas CF. Glomerular involvement in adults with sickle cell hemoglobinopathies: prevalence and clinical correlates of progressive renal failure. J Am Soc Nephrol. 2006;17(8):2228-2235.
384. Bergmann S, Zheng D, Barredo J, Abboud MR, Jaffa AA. Renal kallikrein: a risk marker for nephropathy in children with sickle cell disease. J Pediatr Hematol Oncol. 2006;28(3):147-153.
385. Barros FB, Lima CS, Santos AO, et al. 51Cr-EDTA measurements of the glomerular filtration rate in patients with sickle cell anaemia and minor renal damage. Nucl Med Commun. 2006;27(12):959-962.
386. Tharaux PL, Hagege I, Placier S, et al. Urinary endothelin-1 as a marker of renal damage in sickle cell disease. Nephrol Dial Transplant. 2005;20(11):2408-2413.
387. Bank N, Aynedjian HS, Qiu JH, et al. Renal nitric oxide synthases in transgenic sickle cell mice. Kidney Int. 1996;50:184-189.
388. Montgomery R, Zibari G, Hill GS, Ratner LE. Renal transplantation in patients with sickle cell nephropathy. Transplantation. 1994;58:618-620.
389. Steinberg MH. Erythropoietin in anemia of renal failure in sickle cell disease.NEngl J Med. 1991;324:1369-1370.
390. Ojo AO, Govaerts TC, Schmouder RL, et al. Renal transplantation in end-stage sickle cell nephropathy. Transplantation. 1999;67(2):291-295.
391. Aoki RY, Saad STO. Enalapril reduces the albuminuria of patients with sickle cell disease. Am JMed. 1995;98:432-435.
392. Foucan L, Bourhis V, Bangou J, Mérault L, Etienne-Julan M, Salmi RL. A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia. Am J Med. 1998;104(4):339-342.
393. Rabala A, Guasch A. Effects of angiotensin blockade with losartan on glomerular function in patients with sickle cell glomerulopathy. J AmSoc Nephrol. 2002;13:265A.
394. Wierenga KJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet. 2001;357(9257):680-683.
395. Vichinsky EP, Styles LA, Colangelo LH, et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Blood. 1997;89:1787-1792.
396. Upadhya B, Ntim W, Dworkin J, et al. Prolongation of QTc intervals and risk of sudden death among patients with sickle cell diseases. Blood. 2007;110:667a.
397. Zipursky A, Robieux IC, Brown EJ, et al. Oxygen therapy in sickle cell disease. Am J Pediatr Hematol Oncol. 1992; 14(3):222-228.
398. Hargrave DR, Wade A, Evans JP, Hewes DK, Kirkham FJ. Nocturnal oxygen saturation and painful sickle cell crises in children. Blood. 2003;101(3):846-848.